Avenue Therapeutics, Inc.
Avenue Therapeutics, Inc. is a specialty pharmaceutical company that acquires, licenses, develops and commercializes products principally for use in the U.S. hospital market. Avenue’s lead product candidate is IV Tramadol for the treatment of post-surgical pain. Avenue Therapeutics conducted a PK study to confirm the dose for Phase III and plans to initiate a Phase III development program of IV Tramadol for the management of post-operative pain in 2017. Under the terms of its license agreement, Avenue Therapeutics will have an exclusive license to develop and commercialize IV Tramadol in the United States. Avenue Therapeutics plans to seek additional products to develop in the acute/intensive care hospital market in addition to IV Tramadol. Fortress Biotech currently owns >50% of Avenue Therapeutics.
For more information, please visit www.avenuetx.com.